Zealand slides as Boehringer-partnered obesity drug underwhelms
Zealand slides as Boehringer-partnered obesity drug underwhelms
Zealand Pharma
CPH: ZEAL ~$5B MCAP
Copenhagen-based peptide-based medicines company developing treatments for metabolic and endocrine diseases, including glepaglutide for short bowel syndrome.
Company Info
Upcoming Milestones & Key Dates
Late 2026
Commercial
US launch activities for glepaglutide
2026 H2
Clinical Readout
US obesity pipeline update
Clinical Development Pipeline
Glepaglutide
Target: GLP-2Dasiglucagon
Target: Glucagon receptorUndisclosed
Target: Amylin / GLP-1Recent News
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
Zealand sells rights to Takeda’s blood cancer drug for $100M
Zealand sells rights to Takeda’s blood cancer drug for $100M
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire
Zealand Pharma hires its US marketing leader from Lilly; Bexorg brings in a CSO from Biohaven.
Leadership Team
Adam Steensberg
Chief Executive Officer
Henriette Wennicke
Chief Financial Officer
Chief Commercial Officer
Head of US Marketing